Similar off-tumor side-effects have been reported for approved mAb therapies such as trastuzumab (anti-HER2), which has cardiotoxicity in some patients due to targeting of HER2-mediated cardiomyocyte survival pathways, and cetuximab (anti-EGFR), which produces skin rashes and mucosal irritation related to EGFR expression on epithelial cells (Perez-Soler et al., 2005; Chien, 2006). This evidence concerns the gene ERBB2 and neoplasm.